Pharmacokinetics of levodopa using duodenal levodopa/carbidopa infusion with and without oral COMT inhibitors - DuoCOMT
- Conditions
- Parkinson's disease (G20.9), advanced, patients presently on Duodopa treatment.MedDRA version: 9.1Level: LLTClassification code 10013113Term: Disease Parkinson's
- Registration Number
- EUCTR2008-003581-26-SE
- Lead Sponsor
- Dept of Neuroscience, Uppsala University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Clinically diagnosed Parkinson's disease, ongoing Duodopa therapy.
Age 30-90 years.
At least 4 persons of each gender.
Hoehn & Yahr-stage 3-5 at worst.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Ongoing treatment with COMT-inhibitor.
Dementia.
Psychosis.
Treatment with neuroleptics (atypical neuroleptics are OK).
Liver disease.
Hypersensitivity against Comtess or Tasmar.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method